Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Total Valuation
FibroGen has a market cap or net worth of $41.85M. The enterprise value is $133.15M.
Market Cap$41.85M
Enterprise Value$133.15M
Share Statistics
FibroGen has 4,043,899 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,043,899
Owned by Insiders1.57%
Owned by Institutions13.04%
Financial Efficiency
FibroGen’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is -184.87%.
Return on Equity (ROE)0.21
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-184.87%
Return on Capital Employed (ROCE)-1.85
Revenue Per Employee131.65K
Profits Per Employee-211.46K
Employee Count225
Asset Turnover0.14
Inventory Turnover4.93
Valuation Ratios
The current PE Ratio of FibroGen is ―. FibroGen’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value-5.87
Price to FCF―
Price to Operating Cash Flow-1.65
PEG Ratio―
Income Statement
In the last 12 months, FibroGen had revenue of 29.62M and earned -47.58M in profits. Earnings per share was -0.48.
Revenue29.62M
Gross Profit14.06M
Operating Income-150.42M
Pretax Income-153.37M
Net Income-47.58M
EBITDA-142.43M
Earnings Per Share (EPS)-0.48
Cash Flow
In the last 12 months, operating cash flow was -23.44M and capital expenditures -252.00K, giving a free cash flow of -23.69M billion.
Operating Cash Flow-23.44M
Free Cash Flow-23.69M
Free Cash Flow per Share-5.86
Dividends & Yields
FibroGen pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.92
52-Week Price Change12.93%
50-Day Moving Average7.56
200-Day Moving Average9.32
Relative Strength Index (RSI)63.10
Average Volume (3m)54.39K
Important Dates
FibroGen upcoming earnings date is Nov 10, 2025, After Close (Confirmed).
Last Earnings DateAug 11, 2025
Next Earnings DateNov 10, 2025
Ex-Dividend Date―
Financial Position
FibroGen as a current ratio of 1.47, with Debt / Equity ratio of -40.73%
Current Ratio1.47
Quick Ratio1.45
Debt to Market Cap0.07
Net Debt to EBITDA-0.16
Interest Coverage Ratio-18.24
Taxes
In the past 12 months, FibroGen has paid -269.00K in taxes.
Income Tax-269.00K
Effective Tax Rate<0.01
Enterprise Valuation
FibroGen EV to EBITDA ratio is -9.46, with an EV/FCF ratio of -9.74.
EV to Sales45.48
EV to EBITDA-9.46
EV to Free Cash Flow-9.74
EV to Operating Cash Flow-9.76
Balance Sheet
FibroGen has $23.37M in cash and marketable securities with $93.13M in debt, giving a net cash position of $69.76M billion.
Cash & Marketable Securities$23.37M
Total Debt$93.13M
Net Cash$69.76M
Net Cash Per Share$17.25
Tangible Book Value Per Share-$1.84
Margins
Gross margin is 81.09%, with operating margin of -507.80%, and net profit margin of -160.63%.
Gross Margin81.09%
Operating Margin-507.80%
Pretax Margin-517.76%
Net Profit Margin-160.63%
EBITDA Margin-480.83%
EBIT Margin-489.92%
Analyst Forecast
The average price target for FibroGen is $43.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$43.00
Price Target Upside310.31% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-69.19%
EPS Growth Forecast98.78%